Silence Therapeutics plc SLN
Regular-session close
After hours · Nov 20, 4:00 PM ET
- YTD
- +225.82%
- 1 year
- +211.97%
5D +0.01 (+0.05%)
- Market cap
- 1.23B
- Revenue (ttm)
- 456.00K
- EPS (ttm)
- -1.05
- Shares out
- 62.20M
- Forward P/E
- -24.76
- YTD return
- +225.82%
- 1-year return
- +211.97%
- 50-day average
- 15.15
- 200-day average
- 10.08
- Enterprise value
- 984.67M
- Volume
- 399.15K
- Avg volume
- 2.41M
- Open
- 19.81
- Previous close
- 19.81
- Day's range
- 19.80 – 19.83
- 52-week range
- 4.30 – 19.83
- Beta
- 1.34
- Analysts
- Hold
- Price target
- 19.75 (-0.3%)
- Earnings date
- Mar 4, 2027
Key statistics
- Price / sales
- 2702.28
- Price / book
- 5.73
- Free cash flow
- -25.65M
- Total cash
- 247.66M
- Total debt
- 87.00K
- Return on equity
- -35.58%
- Short % of float
- 4.77%
Fundamental scorecard
5 of 25 checks passed on SLN’s reported financials
5of 25 checks passed
- Value 1 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: hold
- Target (low)
- 19.00
- Target (mean)
- 19.75
- Target (high)
- 20.00
- Strong buy0
- Buy1
- Hold4
- Sell0
- Strong sell0
Next earnings
Mar 4, 2027
Expected Mar 4, 2027. Consensus EPS estimate -0.24.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 4, 2027 | Dec 30, 2026 | -0.08833 | — | — | — |
| Nov 12, 2026 | Sep 30, 2026 | -0.26 | -0.24 | +0.02 | +7.69% |
| Aug 10, 2026 | Jun 30, 2026 | -0.13866 | -0.26 | -0.12 | -87.51% |
| May 7, 2026 | Mar 31, 2026 | -0.33 | -0.32 | +0.01 | +3.03% |
| Mar 5, 2026 | Dec 31, 2025 | -0.32 | -0.25 | +0.07 | +21.88% |
| Nov 6, 2025 | Sep 30, 2025 | -0.40 | -0.45 | -0.05 | -12.50% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 21, 2026 | HC Wainwright & Co. | down | Buy | Neutral |
| Aug 11, 2026 | Morgan Stanley | main | Overweight | Overweight |
| Jun 24, 2026 | Cantor Fitzgerald | init | — | Overweight |
| Jun 17, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Mar 13, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 16, 2025 | HC Wainwright & Co. | reit | Buy | Buy |
About Silence Therapeutics plc
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elevated lipoprotein(a); SLN312 for dyslipidemia; SLN365 for hypercholesterolemia; and SLN098 for obesity. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, United Kingdom.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United Kingdom
- Website
- silence-therapeutics.com
News
Your note
Sign in to keep a note on SLN — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 7.58% | 4,710,812 | 93.32M | Sep 29, 2026 |
| Siren, L.L.C. | 4.65% | 2,887,867 | 57.21M | Sep 29, 2026 |
| Citadel Advisors Llc | 4.55% | 2,825,601 | 55.98M | Sep 29, 2026 |
| Redmile Group, LLC | 3.96% | 2,460,894 | 48.75M | Sep 29, 2026 |
| Tetragon Partners GP Ltd. | 3.92% | 2,436,051 | 48.26M | Sep 29, 2026 |
| Soleus Capital Management, L.P. | 3.84% | 2,385,700 | 47.26M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 2.66% | 1,654,900 | 32.78M | Sep 29, 2026 |
| Fidelity Securities Fund-Fidelity Small Cap Growth Fund | 1.47% | 915,010 | 18.13M | Aug 30, 2026 |
| Fidelity Advisor Series VII-Fidelity Advisor Biotechnology Fund | 0.86% | 531,788 | 10.53M | Sep 29, 2026 |
| Fidelity Select Portfolios-Select Health Care Portfolio | 0.80% | 500,000 | 9.90M | Sep 29, 2026 |
| Fidelity Securities Fund-Fidelity Small Cap Growth K6 Fund | 0.77% | 478,510 | 9.48M | Aug 30, 2026 |
| iShares Trust-iShares Biotechnology ETF | 0.47% | 289,972 | 5.74M | Sep 29, 2026 |
